-
- Position
- PROFESSOR | Medicine, Cardiology
-
- Specialty
- Cardiology
-
- Languages
- English
- Spanish
-
- Hospital Affiliation
- The Mount Sinai Hospital
-
- Phone
- 212-241-9454212-241-9454
New York, NY 10029
Phone: 212-241-9454212-241-9454
Dr. Olin is a Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Director of Vascular Medicine and the Vascular Diagnostic Laboratory in the Zena and Michael A. Wiener Cardiovascular Institute and Marie-Josée and Henry R. Kravis Center for Cardiovascular Health of The Mount Sinai Medical Center.
Dr. Olin is an internationally recognized expert in the field of Vascular Medicine. He has held numerous leadership positions and has been at the forefront of establishing Vascular Medicine as a distinct subspecialty of Cardiovascular Medicine. He was instrumental in the formation of the American Board of Vascular Medicine, the first ever board examination in this specialty. Dr. Olin is a past president of the Society for Vascular Medicine and recently has been awarded the highest honor from that society, Master of the Society for Vascular Medicine. He is a Fellow of the American College of Cardiology and a Fellow of the American Heart Association. Dr Olin received the inaugural Jess R Young, M.D. teaching award from the Society for Vascular Medicine and in 2013 he received the Simon Dack, M.D. teaching award from the fellows at the Zena and Michael A. Wiener Cardiovascular Institute and Marie-Josée and Henry R. Kravis Center for Cardiovascular Health of the Mount Sinai Medical Center.
He is a past member of the peripheral vascular disease committee of the American College of Cardiology and past Chair of the Interdisciplinary Working Group on Atherosclerotic Peripheral Vascular Disease of the American Heart Association. He played an important role in the transformation of this working group to that of a Council of the American Heart Association. He was a member of the Board of Directors of the American Board of Vascular Medicine and is one of four physicians selected to direct a task force leading to an examination in the certification entitled Registered Physician in Vascular Ultrasound (RPVI).
Dr. Olin has been involved in clinical research involving venous thromboembolic disease, fibromuscular dysplasia, peripheral artery disease, renal artery disease and carotid artery disease. He is on the international steering committee for the EUCLID Trial to determine the most effective antiplatelet regimen in patients with peripheral artery disease. He is also on the international steering committee for placental stem cell therapy to treat patients with peripheral artery disease. He is the chair of the steering committee and PI for the United States Registry for Fibromuscular Dysplasia and Chair of the Medical Advisory Board of the Fibromuscular Dysplasia Society of America. He is the Director for the Mount Sinai Heart Center for Fibromuscular Dysplasia Care and Research where he is working on defining the genetics of fibromuscular dysplasia.
Dr. Olin has authored more than 220 scientific papers in the peer review literature, 3 books and more than 70 book chapters. He has served on many writing committees of the American College of Cardiology and American Heart Association. He chaired the writing committee on Performance Measures in Peripheral Arterial Disease, and the Scientific Statement from the American Heart Association entitled Fibromuscular Dysplasia: State of the Science and Critical Unanswered Questions. He was a member of the task force on the development of Appropriate Use Criteria for vascular ultrasound.. He has published in the New England Journal of Medicine, Circulation, Journal of the American Medical Association, Journal of the American College of Cardiology, Journal of Vascular Surgery and Vascular Medicine to name a few. He is a past Associate Editor of the journal Vascular Medicine, and current Associate Editor for the Journal of the American College of Cardiology and Editor of the textbook Peripheral Vascular Diseases.
In The News: Dr. Jeffrey Olin discusses fibromuscular dysplasia in the The Daily News feature The Daily Check-Up. His program on fibromuscular dysplasia is discussed in the Wall Street Journal article on "The Rare Disease that Isn't" http://online.wsj.com/news/articles/SB124605981966763611
Certifications
Nephrology
American Board of Internal Medicine
Clinical Focus
- Carotid Artery Stenosis
- Deep Vein Thrombosis
- High Blood Pressure
- Peripheral Vascular Disease
- Pulmonary Embolism
- Raynaud's Disease And Phenomenon
- Renal Artery Stenosis
- Renovascular Hypertension
Education
DO, University of Kansas
Residency, Internal Medicine
Cleveland Clinic Foundation
Fellowship, Nephrology
Cleveland Clinic Foundation
Languages
English, Spanish
2014
Associate Editor, Journal of the American College of Cardiology
American College of Cardiology
2013
Simon Dack, M.D. Teaching Award
Mount Sinai Heart
This award is given by the cardiology fellows to the attending physician was the outstanding teacher of the year.
2012
Scientific Program Committee
American College of Cardiology
2011
Jess R Young, M.D. Teaching Award
Society for Vascular Medicine
Dr Olin is the first person to receive this award which honor the physician who contributed the most to the education in the field of vascular medicine
2010
Steering Committee
Appropriate Use Criteria Peripheral Arterial Disease American College of Cardiology
2010
Chair American Heart Association Scientific Statement
Fibromuscular Dysplasia: State of the Science and Critical Unanswered Questions
2008
Chair Writing Committee
American College of Cardiology
American Heart Association Performance Measures on Peripheral Artery Disease
2008
Master of the Society for Vascular Medicine
Society for Vascular Medicine
Dr. Olin is the 4th person to receive this award in the Society.
2005
Chair
Interdisciplinary Working Group on Atherosclerotic Peripheral Vascular Disease of the American Heart Association
2004
Present Chair
Medical Advisory Board Fibromuscular Dysplasia Society of America
2004
Associate Editor
Vascular Medicine
2002
Peripheral Vascular Disease Steering Committee of the American Heart Association
1999
President
Society for Vascular Medicine and Biology
1991
Fellow
Society of Vascular Medicine and Biology
1991
Fellow
American College of Cardiology
1987
Fellow
American College of Physicians
1983
Outstanding Teacher Award
Department of Medicine the Western Pennsylvania Hospital
Clinical Trials
Fibromuscular dysplasia international society registry
Fibromuscular dysplasia (FMD) is a non-atherosclerotic, non-inflammatory vascular disease that most commonly affects the renal and internal carotid arteries but has been described in almost every arterial bed in the body. The purpose of this study is to collect information regard...
Endothelial Function in Fibromuscular Dysplasia
Fibromuscular dysplasia is a blood vessel disease that has been reported in almost every part of the body. It primarily affects women 15-50 years old and can cause high blood pressure, kidney disease and other blood vessel problems. The purpose of this study is to evaluate bloo...
Olin JW. Thromboangiitis Obliterans (Buerger's Disease). N Engl J Med 2000; 343: 864-869.
Slovut DP, Olin JW. Fibromuscular Dysplasia. N Engl J Med 2004; 350: 1862-71.
Olin JW. Society for Vascular Medicine and Biology Presidential Address. A vision for the . Vasc Med 2000; 5: 205-207.
Massullo-LaPerna L, Olin JW, Goines D, Ouriel K. Ultrasound guided thrombin injection for the. Circulation 2000; 102: 2391-5.
Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317-1324.
Olin JW. Is fibromuscular dysplasia a single disease?. Circulation 2012 Dec; 126(25).
Kim ES, Olin JW, Froehlich JB, Gu X, Bacharach JM, Gray BH, Jaff MR, Katzen BT, Kline-Rogers E, Mace PD, Matsumoto AH, McBane RD, White CJ, Gornik HL. Clinical manifestations of fibromuscular dysplasia vary by patient sex: a report of the United States registry for fibromuscular dysplasia. Journal of the American College of Cardiology 2013 Nov; 62(21).
Del Conde I, Galin ID, Trost B, Kang J, Lookstein R, Woodward M, Gustavson S, Cambria RP, Jaff MR, Olin JW. Renal artery duplex ultrasound criteria for the detection of significant in-stent restenosis. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2013 Oct;.
Olin JW, Sealove BA. Diagnosis, management, and future developments of fibromuscular dysplasia. Journal of vascular surgery 2011 Mar; 53(3).
Creager MA, Olin JW, Belch JJ, Moneta GL, Henry TD, Rajagopalan S, Annex BH, Hiatt WR. Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Circulation 2011 Oct; 124(16).
Olin JW, Allie DE, Belkin M, Bonow RO, Casey DE, Creager MA, Gerber TC, Hirsch AT, Jaff MR, Kaufman JA, Lewis CA, Martin ET, Martin LG, Sheehan P, Stewart KJ, Treat-Jacobson D, White CJ, Zheng ZJ, Masoudi FA. ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010 performance measures for adults with peripheral artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on performance measures, the American College of Radiology, the Society for Cardiac Angiography and Interventions, the Society for Interventional Radiology, the Society for Vascular Medicine, the Society for Vascular Nursing, and the Society for Vascular Surgery (Writing Committee to Develop Clinical Performance Measures for Peripheral Artery Disease). Circulation 2010 Dec; 122(24).
Olin JW, Froehlich J, Gu X, Bacharach JM, Eagle K, Gray BH, Jaff MR, Kim ES, Mace P, Matsumoto AH, McBane RD, Kline-Rogers E, White CJ, Gornik HL. The United States Registry for Fibromuscular Dysplasia: results in the first 447 patients. Circulation 2012 Jun; 125(25).
Weinberg MD, Lau JF, Rosenfield K, Olin JW. Peripheral artery disease. Part 2: medical and endovascular treatment. Nature reviews. Cardiology 2011 Aug; 8(8).
Mohler ER, Gornik HL, Gerhard-Herman M, Misra S, Olin JW, Zierler RE, Wolk MJ, Mohler ER. ACCF/ACR/AIUM/ASE/ASN/ICAVL/SCAI/SCCT/SIR/SVM/SVS/SVU [corrected] 2012 appropriate use criteria for peripheral vascular ultrasound and physiological testing part I: arterial ultrasound and physiological testing: a report of the American College of Cardiology Foundation appropriate use criteria task force, American College of Radiology, American Institute of Ultrasound in Medicine, American Society of Echocardiography, American Society of Nephrology, Intersocietal Commission for the Accreditation of Vascular Laboratories, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Interventional Radiology, Society for Vascular Medicine, Society for Vascular Surgery, [corrected] and Society for Vascular Ultrasound. [corrected]. Journal of the American College of Cardiology 2012 Jul; 60(3).
Nead KT, Zhou M, Diaz Caceres R, Olin JW, Cooke JP, Leeper NJ. Walking impairment questionnaire improves mortality risk prediction models in a high-risk cohort independent of peripheral arterial disease status. Circulation. Cardiovascular quality and outcomes 2013 May; 6(3).
Nead KT, Cooke JP, Olin JW, Leeper NJ. Alternative ankle-brachial index method identifies additional at-risk individuals. Journal of the American College of Cardiology 2013 Aug; 62(6).
Weinberg I, Keyes MJ, Giri J, Rogers KR, Olin JW, White CJ, Jaff MR. Blood pressure response to renal artery stenting in 901 patients from five prospective multicenter FDA-approved trials. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2013 Oct;.
Lau JF, Weinberg MD, Olin JW. Peripheral artery disease. Part 1: clinical evaluation and noninvasive diagnosis. Nature reviews. Cardiology 2011 Jul; 8(7).
White CJ, Olin JW. Diagnosis and management of atherosclerotic renal artery stenosis: improving patient selection and outcomes. Nature clinical practice. Cardiovascular medicine 2009 Mar; 6(3).
Weinberg MD, Olin JW. Stenting for atherosclerotic renal artery stenosis: one poorly designed trial after another. Cleveland Clinic journal of medicine 2010 Mar; 77(3).
Olin JW, Gornik HL, Bacharach JM, Biller J, Fine LJ, Gray BH, Gray WA, Gupta R, Hamburg NM, Katzen BT, Lookstein RA, Lumsden AB, Newburger JW, Rundek T, Sperati CJ, Stanley JC. Fibromuscular dysplasia: state of the science and critical unanswered questions: a scientific statement from the American Heart Association. Circulation 2014 Mar; 129(9).
Olin JW, Kadian-Dodov D. Exercise-induced leg pain and high blood pressure. JAMA; 311(4).
Reddy VY, Olin JW. Renal denervation for resistant hypertension: not dead yet. Journal of the American College of Cardiology 2014 Sep; 64(11).
Michelis KC, Olin JW, Kadian-Dodov D, d'Escamard V, Kovacic JC. Coronary Artery Manifestations of Fibromuscular Dysplasia. Journal of the American College of Cardiology 2014 Sep; 64(10).
Sethi SS, Lau JF, Godbold J, Gustavson S, Olin JW. The S curve: A novel morphological finding in the internal carotid artery in patients with fibromuscular dysplasia. Vascular medicine (London, England) 2014 Aug;.
Chang P, Nead KT, Olin JW, Cooke JP, Leeper NJ. Clinical and socioeconomic factors associated with unrecognized peripheral artery disease. Vascular medicine (London, England) 2014 May; 19(4).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Olin during 2016 and/or 2017. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Northwind Medical
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- AstraZeneca
- Pluristem Therapeutics Inc.
Scientific Advisory Board:
- Merck & Co., Inc.
- Novartis
- Pluristem Therapeutics Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.